Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label Phase II study.
Mariette X, Seror R, Quartuccio L et al.
Université Paris-Sud, Paris, France.
» Read an expert review of this paper
Ann Rheum Dis 2013 Dec 17; Epub ahead of print.
Gerard Espinosa’s review: Belimumab, an inhibitor of B lymphocyte stimulator (BLyS), has been shown to be effective in patients with systemic lupus erythematosus (SLE) and has been approved in the US and Europe for the treatment of this disease.